Prospective Evaluation of Immune-related Markers and Gallbladder Cancer
Principal Investigator
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
2014-0198
Initial CDAS Request Approval
Sep 3, 2014
Title
Prospective Evaluation of Immune-related Markers and Gallbladder Cancer
Summary
Inflammation is a strong risk factor for gallbladder cancer (GBC). However, few studies have evaluated biological markers of inflammation and other immune-related processes. In a preliminary study in the Shanghai Biliary Tract Cancer Study, we used multiplexed assays to measure 71 immune-related markers in serum and bile from 41 GBC cases and 127 gallstone (GS) controls. Many markers were strongly associated with GBC versus GS based on measurements in both serum and bile; comparing the highest marker level group vs. the lowest group (categories based on percentage of individuals with detectable values), 19 markers (29%) were significantly associated with GBC risk in both serum and bile. We observed a similar pattern of associations between circulating immune markers and GBC compared to GS in an independent study population from Chile. These results suggest that serum measurements reflect the inflammatory processes at work in the gallbladder itself and that these associations are robust. However, we cannot rule out the potential for disease effect.
To address this issue, we propose to measure pre-diagnostic immune marker levels in GBC cases and matched controls to evaluate the association between pre-diagnostic immune marker levels and GBC risk. We have been approved to test 17 GBC cases with pre-diagnostic serum and matched controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, and we would like to expand these efforts to include pre-diagnostic samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and other cohorts. In PLCO, we propose to test circulating immune marker levels in baseline serum samples from 25 cases and matched controls.
To address this issue, we propose to measure pre-diagnostic immune marker levels in GBC cases and matched controls to evaluate the association between pre-diagnostic immune marker levels and GBC risk. We have been approved to test 17 GBC cases with pre-diagnostic serum and matched controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, and we would like to expand these efforts to include pre-diagnostic samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and other cohorts. In PLCO, we propose to test circulating immune marker levels in baseline serum samples from 25 cases and matched controls.
Aims
Based on our previous results, we hypothesize that immune marker levels, particularly for C-reactive protein (CRP), interleukin-8 (IL-8), macrophage-derived chemokine (MDC), serum amyloid A (SAA), soluble epithelial growth factor receptor (sEGFR), and soluble tumor necrosis factor II (sTNFII), will be associated with GBC. We propose to measure 71 immune markers in baseline serum from 25 gallbladder cancer cases and 100 age-, sex-, and blood-draw frequency matched controls with and without reported gallstones or gallbladder inflammation in PLCO and to combine these results with those of other cohorts.
Collaborators
-